SCHEMBL24676590

SCHEMBL24676590

Cc1sc2ccn(Cc3ccc(S(F)(F)(F)(F)F)cc3)c2c1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.36
HDAC6 Q9UBN7 1/20 0.31
PTGER4 P35408 2/20 0.31
PTGDR Q13258 2/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
TP53 P04637 3/20 0.31
KDM4E B2RXH2 2/20 0.31
CYP2D6 P10635 2/20 0.31
HTT P42858 2/20 0.31
POLB P06746 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
GAA P10253 1/20 0.31
THRB P10828 1/20 0.31
NR4A1 P22736 1/20 0.31
APEX1 P27695 1/20 0.31
APOBEC3A P31941 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24676580 0.89 ALDH1A1 (0.33) NOTUMHDAC6SMN1; SMN2KDM4ECYP2D6
SCHEMBL26908087 0.87 HSP90B1 (0.34) HDAC6SMN1; SMN2TP53ALDH1A1MAPT
SCHEMBL24676880 0.82 PTGER4 (0.51) PTGER4PTGDR
SCHEMBL24677077 0.80 PTGER4 (0.52) PTGER4PTGDR
SCHEMBL29260289 0.80 PTGER4 (0.43) PTGER4PTGDRSMN1; SMN2KDM4EPOLB
SCHEMBL24676582 0.75 PTGER4 (0.43) PTGER4PTGDRHTTMAPTMEN1
SCHEMBL30516662 0.75 BACE1 (0.39) PTGER4SMN1; SMN2TP53
SCHEMBL26784942 0.75 BACE1 (0.39) PTGER4SMN1; SMN2TP53
SCHEMBL1845684 0.72 KDM4E (0.44) PTGER4PTGDRSMN1; SMN2KDM4EHTT
SCHEMBL31613309 0.71 PTGER4 (0.43) PTGER4PTGDRSMN1; SMN2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399339-A1 HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) 2023-12-14 US disclosed
EP-4286390-A1 HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2023-12-06 EP disclosed
CN-116783201-A Heterocyclic amide derivative, preparation method and application thereof 深圳众格生物科技有限公司 2023-09-19 CN disclosed
WO-2022161422-A1 HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 深圳晶泰科技有限公司 2022-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399339-A1 HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF PTGER4, PTGER1, EPB41 NOTUM 4/4885HDAC6 1432/4885PTGER4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.